148 related articles for article (PubMed ID: 32221862)
1. Changes in neutrophil to lymphocyte ratio (NLR) during neoadjuvant treatment correlated with patients' survival.
Choi H; Noh H; Cho IJ; Lim ST; Han A
Breast Cancer; 2020 Sep; 27(5):871-879. PubMed ID: 32221862
[TBL] [Abstract][Full Text] [Related]
2. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
[TBL] [Abstract][Full Text] [Related]
3. Can the Neutrophil to Lymphocyte Ratio Predict Complete Pathologic Response to Neoadjuvant Breast Cancer Treatment? A Systematic Review and Meta-analysis.
Cullinane C; Creavin B; O'Leary DP; O'Sullivan MJ; Kelly L; Redmond HP; Corrigan MA
Clin Breast Cancer; 2020 Dec; 20(6):e675-e681. PubMed ID: 32653471
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Different Phenotypes of Locally Advanced Breast Cancer During Neoadjuvant Systemic Treatment.
Muñoz-Montaño W; Cabrera-Galeana P; Alvarado-Miranda A; Villarreal-Garza C; Mohar A; Olvera A; Bargallo-Rocha E; Lara-Medina F; Arrieta O
Clin Breast Cancer; 2020 Aug; 20(4):307-316.e1. PubMed ID: 32305297
[TBL] [Abstract][Full Text] [Related]
5. The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
Dan J; Tan J; Huang J; Zhang X; Guo Y; Huang Y; Yang J
Breast Cancer; 2020 Sep; 27(5):982-988. PubMed ID: 32306184
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
[TBL] [Abstract][Full Text] [Related]
7. Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4.
el Aziz LM
Med Oncol; 2014 Dec; 31(12):311. PubMed ID: 25367855
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy.
Marín Hernández C; Piñero Madrona A; Gil Vázquez PJ; Galindo Fernández PJ; Ruiz Merino G; Alonso Romero JL; Parrilla Paricio P
Clin Transl Oncol; 2018 Apr; 20(4):476-483. PubMed ID: 28785911
[TBL] [Abstract][Full Text] [Related]
9. Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy.
Jin H; Zhang G; Liu X; Liu X; Chen C; Yu H; Huang X; Zhang Q; Yu J
World J Surg Oncol; 2013 May; 11():112. PubMed ID: 23705622
[TBL] [Abstract][Full Text] [Related]
10. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
[TBL] [Abstract][Full Text] [Related]
11. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
Resende U; Cabello C; Ramalho SOB; Zeferino LC
BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer.
Chae S; Kang KM; Kim HJ; Kang E; Park SY; Kim JH; Kim SH; Kim SW; Kim EK
Curr Oncol; 2018 Apr; 25(2):e113-e119. PubMed ID: 29719435
[TBL] [Abstract][Full Text] [Related]
13. Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation.
Shen L; Zhang H; Liang L; Li G; Fan M; Wu Y; Zhu J; Zhang Z
Radiat Oncol; 2014 Dec; 9():295. PubMed ID: 25518933
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy.
Bae SJ; Cha YJ; Yoon C; Kim D; Lee J; Park S; Cha C; Kim JY; Ahn SG; Park HS; Park S; Kim SI; Jeong J
Sci Rep; 2020 Aug; 10(1):13078. PubMed ID: 32753659
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting.
Grassadonia A; Graziano V; Iezzi L; Vici P; Barba M; Pizzuti L; Cicero G; Krasniqi E; Mazzotta M; Marinelli D; Amodio A; Natoli C; Tinari N
Cells; 2021 Jul; 10(7):. PubMed ID: 34359855
[TBL] [Abstract][Full Text] [Related]
16. The predictive potential of Neuronatin for neoadjuvant chemotherapy of breast cancer.
Pieper W; Ignatov A; Kalinski T; Haybaeck J; Czapiewski P; Nass N
Cancer Biomark; 2021; 32(2):161-173. PubMed ID: 34092612
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of the Neutrophil-to-Lymphocyte Ratio in Endocrine Therapy for Stage IV Breast Cancer.
Iimori N; Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Hirakawa K; Ohira M
In Vivo; 2018; 32(3):669-675. PubMed ID: 29695577
[TBL] [Abstract][Full Text] [Related]
18. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
[TBL] [Abstract][Full Text] [Related]
19. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
Graziano V; Grassadonia A; Iezzi L; Vici P; Pizzuti L; Barba M; Quinzii A; Camplese A; Di Marino P; Peri M; Veschi S; Alberti S; Gamucci T; Di Gioacchino M; De Tursi M; Natoli C; Tinari N
Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
[TBL] [Abstract][Full Text] [Related]
20. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]